Back to News
Market Impact: 0.32
Keros Therapeutics Authorises $ 5 Mln Share Buyback Following Elritercept Milestone; Stock Up
Source: Nasdaq
Capital Returns (Dividends / Buybacks)Healthcare & BiotechCompany Fundamentals
Keros Therapeutics' board approved a $5 million share-repurchase program after the clinical-stage biotech received a $20 million elritercept milestone payment from partner Takeda Pharmaceuticals. The buyback represents 25% of the milestone proceeds and signals management confidence while returning part of the partnership-related cash inflow to shareholders.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
KROS0.58
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- How Pepsi fell behind in the cola wars—and then lost KFC
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- Braskem creditors, shareholders near deal on $11bn debt restructuring
- Xencor reports phase 1 data for cancer drug XmAb819
- The experience economy keeps defying expectations. Maybe we’ve been looking at it all wrong